89% of Businesses Forecast Revenue Growth with Digital ID Adoption, Regula Survey Reveals
Regula, a global developer of forensic devices and identity verification solutions, has released new findings from its study “The New Imperative: Digital IDs,” which unveil how companies worldwide assess their revenue transformation after digital ID implementation. These findings also highlight the use cases where the digital ID adoption will have the most notable effect.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240805603877/en/
Regula's study uncovers how companies globally evaluate revenue transformation post-digital ID implementation, with an overwhelmingly positive outlook. (Graphic: Regula)
Forrester Consulting, commissioned by Regula to conduct “The New Imperative: Digital IDs” study, underlines that most respondents, 89%, anticipate a positive impact on revenue from the adoption of digital IDs. Specifically, 32% of businesses anticipate a 20%-29% rise in revenue, 23% foresee a 10%-19% increase, 16% predict a boost of over 30%, and 18% expect up to a 10% growth.
Interestingly, the Middle East seems to be more optimistic about adopting digital IDs. Only 4% of respondents in this region think that there will be no significant change in revenue, which is much lower than the global rate (10%) or the one in Europe, where 13% of businesses do not expect any change.
The most promising areas
“The New Imperative: Digital IDs” study indicates that the benefits from digital ID implementation will be most noticeable and yield the fastest results in the following top five use cases:
- online financial transactions (46% of respondents globally);
- online account opening (38%);
- eCommerce transactions (33%);
- eGovernment services (32%);
- remote customer onboarding (31%).
The Forrester Consulting study underlines: “These results highlight a significant expectation that digital IDs will enhance efficiency, security, and user experience in sectors where identity verification plays a crucial role in transaction security and customer trust.”
Regional Differences
For the region of North America, the most significant effect is expected to be experienced with online financial transactions (51%), online account opening (39%), remote customer onboarding (36%), and eCommerce transactions (35%). All of these rates are higher than the global. Interestingly, the region is rather more inclined to enhance age verification through digital IDs, with 21% expecting to see improvements in this use case (globally, this rate is 19%, and in the Middle East it is 14%).
In Europe, businesses share the global expectations. Thus, 44% anticipate seeing positive changes in online financial transactions, 38% – in online account opening, 36% – in eGovernment services, 30% – in remote customer onboarding, and 29% – in mobile device access. Europe seems to be more determined to improve eGovernment services: 36% of respondents here (compared to 32% globally) expect to benefit from adopting digital IDs.
In the Middle East, the study respondents express their expectations to see improvements in online financial transactions (44%) and online account opening (35%), though these rates are slightly lower than global. More than the other regions, the Middle East expects to see positive changes in workplace access and remote work (30%, compared to 25% global and 24% in Europe and North America), and healthcare services access (26% compared to 15% global and 9% in Europe).
“Businesses are shifting their approach to identity verification. Once merely a legal requirement or a commodity, it has now become a technological advancement and a strategic imperative. Our study shows that companies worldwide see the transformative potential of digital IDs to boost revenue, enhance security, and improve user experience. As we innovate and deliver advanced identity verification solutions, we are dedicated to helping businesses unlock these benefits and thrive in the digital era,” says Ihar Kliashchou, Chief Technology Officer at Regula.
If you are interested in getting more insights from the study, “The New Imperative: Digital IDs,” please download a complimentary copy from the Regula website.
Additional resources:
- 42% of companies globally are ready to implement Digital ID
- Digital IDs are not going to replace physical documents
- Regional expectations for digital ID fraud reduction
- EU Digital Identity Wallet: Exploring Its Current Potential
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805603877/en/
Contacts
Kristina – ks@regulaforensics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom